Emergent BioSolutions Inc. (NYSE:EBS) Director Keith Katkin Sells 7,844 Shares

Emergent BioSolutions Inc. (NYSE:EBS - Get Free Report) Director Keith Katkin sold 7,844 shares of the stock in a transaction on Friday, May 23rd. The stock was sold at an average price of $6.30, for a total value of $49,417.20. Following the completion of the transaction, the director now directly owns 86,431 shares in the company, valued at $544,515.30. This trade represents a 8.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Emergent BioSolutions Trading Down 1.8%

Shares of Emergent BioSolutions stock traded down $0.12 on Friday, reaching $6.35. 901,777 shares of the company were exchanged, compared to its average volume of 1,845,674. Emergent BioSolutions Inc. has a fifty-two week low of $4.02 and a fifty-two week high of $15.10. The firm has a market capitalization of $344.39 million, a price-to-earnings ratio of -1.55 and a beta of 2.09. The company has a current ratio of 2.88, a quick ratio of 1.47 and a debt-to-equity ratio of 1.30. The stock has a fifty day moving average price of $5.31 and a 200-day moving average price of $7.55.

Emergent BioSolutions (NYSE:EBS - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.71 earnings per share for the quarter, topping the consensus estimate of $0.49 by $0.22. The firm had revenue of $222.20 million for the quarter, compared to analysts' expectations of $218.50 million. Emergent BioSolutions had a negative net margin of 18.55% and a negative return on equity of 9.91%. On average, analysts expect that Emergent BioSolutions Inc. will post -0.63 EPS for the current year.

Emergent BioSolutions declared that its board has authorized a share repurchase plan on Monday, March 31st that allows the company to buyback $50.00 million in outstanding shares. This buyback authorization allows the biopharmaceutical company to reacquire up to 19% of its stock through open market purchases. Stock buyback plans are often a sign that the company's management believes its shares are undervalued.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on EBS. Wall Street Zen lowered shares of Emergent BioSolutions from a "buy" rating to a "hold" rating in a report on Wednesday, March 5th. HC Wainwright reissued a "buy" rating and issued a $15.00 price target on shares of Emergent BioSolutions in a report on Tuesday, April 1st.

Institutional Investors Weigh In On Emergent BioSolutions

Several institutional investors and hedge funds have recently modified their holdings of the business. Acadian Asset Management LLC increased its position in Emergent BioSolutions by 313.5% during the first quarter. Acadian Asset Management LLC now owns 833,316 shares of the biopharmaceutical company's stock worth $4,048,000 after buying an additional 631,794 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Emergent BioSolutions by 12.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,090,655 shares of the biopharmaceutical company's stock valued at $5,301,000 after acquiring an additional 121,583 shares during the last quarter. Millennium Management LLC increased its holdings in shares of Emergent BioSolutions by 68.9% during the 1st quarter. Millennium Management LLC now owns 2,502,488 shares of the biopharmaceutical company's stock valued at $12,162,000 after acquiring an additional 1,020,582 shares during the last quarter. Jacobs Levy Equity Management Inc. raised its stake in shares of Emergent BioSolutions by 6.0% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 196,384 shares of the biopharmaceutical company's stock valued at $954,000 after acquiring an additional 11,067 shares in the last quarter. Finally, EP Wealth Advisors LLC lifted its holdings in Emergent BioSolutions by 33.1% in the 1st quarter. EP Wealth Advisors LLC now owns 15,249 shares of the biopharmaceutical company's stock worth $74,000 after purchasing an additional 3,790 shares during the last quarter. Institutional investors and hedge funds own 78.40% of the company's stock.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.